Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

PROCEPT BioRobotics Corporation PRCT

Healthcare  —  Medical Devices
17.20 (0.30) (1.71%) as of 25 Sep
Market cap
$1.0B
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

PROCEPT BioRobotics Corporation (PRCT) Business Profile

Updated before January 2025

Company Overview

PROCEPT BioRobotics Corporation (PRCT) is a pioneering medical technology company specializing in the development of innovative robotic solutions for urology. Founded in 2007 and headquartered in Redwood City, California, PRCT has established itself as a leader in the field of minimally invasive surgical solutions. The company was co-founded by Michael Zhao and Nikolai Aljuri, with a vision to revolutionize the treatment of urological conditions through advanced robotics and automation. The current leadership team includes Reza Zadno, who serves as the President and CEO, bringing decades of experience in medical technology and innovation. Under his guidance, PRCT has achieved significant milestones in product development and market expansion.

Core Business Segments

Robotic Surgical Systems

PRCT’s flagship product is the AquaBeam Robotic System, a state-of-the-art surgical platform designed for the treatment of benign prostatic hyperplasia (BPH). This system utilizes waterjet technology, known as Aquablation therapy, to provide a minimally invasive and highly precise treatment option for patients. The AquaBeam Robotic System is the first and only image-guided robotic therapy for BPH, offering unparalleled accuracy and safety.

Clinical Support and Training

In addition to its robotic systems, PRCT offers comprehensive clinical support and training programs for healthcare providers. These programs ensure that surgeons and medical staff are well-equipped to utilize the AquaBeam Robotic System effectively, thereby improving patient outcomes and satisfaction.

Research and Development

PRCT invests heavily in research and development to expand its product portfolio and enhance the capabilities of its existing technologies. The company is committed to advancing the field of urology through continuous innovation and collaboration with leading medical institutions.

Business Model

PRCT operates on a business model that integrates cutting-edge technology with robust clinical support services. The company generates revenue primarily through the sale of its AquaBeam Robotic System and associated consumables, such as single-use handpieces and accessories. Additionally, PRCT offers maintenance and support services, creating a recurring revenue stream. By focusing on both product sales and service offerings, PRCT ensures a sustainable and scalable business model.

Strategic Direction

PRCT’s strategic direction is centered on expanding its global footprint and driving innovation in urological care. The company aims to:

  • Expand Market Penetration: PRCT is focused on increasing the adoption of the AquaBeam Robotic System in hospitals and surgical centers worldwide. This includes entering new geographic markets and strengthening its presence in existing ones.
  • Enhance Product Portfolio: The company is actively exploring new applications for its waterjet technology and developing next-generation robotic systems to address a broader range of urological conditions.
  • Sustainability Goals: PRCT is committed to reducing its environmental impact by adopting sustainable manufacturing practices and minimizing waste associated with its products.
  • Collaborative Research: PRCT plans to collaborate with leading academic and medical institutions to advance clinical research and validate the efficacy of its technologies.

Competitive Landscape

PRCT operates in a highly competitive market, facing competition from both established medical device companies and emerging startups. Key competitors include:

  • Intuitive Surgical: Known for its da Vinci Surgical System, Intuitive Surgical is a dominant player in the robotic surgery market.
  • Boston Scientific: A major competitor in the field of urology, offering a wide range of products for the treatment of BPH and other conditions.
  • Medtronic: A global leader in medical technology, Medtronic competes with PRCT in the broader surgical robotics space.
  • Teleflex: Specializes in minimally invasive surgical solutions, including products for urological procedures.

Despite the competition, PRCT differentiates itself through its unique waterjet technology and focus on urology-specific solutions.

Risk Factors

PRCT faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the success of its AquaBeam Robotic System. Any decline in demand or negative clinical outcomes could adversely affect its revenue.
  • Regulatory Challenges: As a medical device company, PRCT must navigate complex regulatory environments in different countries, which can delay product approvals and market entry.
  • Supply Chain Disruptions: Dependence on third-party suppliers for components and materials exposes PRCT to potential supply chain disruptions.
  • Competition: Intense competition from larger, well-established companies could limit PRCT’s market share and pricing power.

Recent Developments

PRCT has made significant strides in recent years, including:

  • FDA Approvals: The AquaBeam Robotic System received FDA clearance for expanded indications, allowing it to be used in a broader range of patients.
  • Global Expansion: PRCT has entered new international markets, including Europe and Asia, to increase the adoption of its technologies.
  • Clinical Studies: The company has published several peer-reviewed studies demonstrating the safety and efficacy of Aquablation therapy, further validating its technology.
  • Strategic Partnerships: PRCT has partnered with leading healthcare providers to enhance training programs and improve patient access to its robotic systems.

Investment Considerations

Strengths

  • Innovative Technology: PRCT’s AquaBeam Robotic System is a groundbreaking solution in the field of urology, offering significant advantages over traditional surgical methods.
  • Growing Market: The global market for robotic surgical systems is expected to grow rapidly, providing ample opportunities for PRCT.
  • Strong Leadership: The company’s experienced leadership team has a proven track record of driving innovation and growth.

Risks

  • High Dependence on a Single Product: PRCT’s reliance on the AquaBeam Robotic System makes it vulnerable to market fluctuations and competitive pressures.
  • Regulatory and Compliance Risks: Navigating the complex regulatory landscape poses challenges for product approvals and market entry.
  • Financial Performance: As a relatively young company, PRCT may face challenges in achieving consistent profitability.

Conclusion

PROCEPT BioRobotics Corporation is a trailblazer in the field of robotic urology, offering innovative solutions that improve patient outcomes and streamline surgical procedures. With its cutting-edge AquaBeam Robotic System, strong focus on research and development, and strategic growth initiatives, PRCT is well-positioned to capitalize on the growing demand for robotic surgical systems. However, investors should carefully consider the risks associated with market dependence, regulatory challenges, and competition. Overall, PRCT’s commitment to innovation and excellence makes it a compelling player in the medical technology industry.